Assisted Reproductive Technology and Risk of Childhood Cancer Among the Offspring of Parents With Infertility: Systematic Review and Meta-Analysis.

IF 3.3 Q2 ONCOLOGY
JMIR Cancer Pub Date : 2025-03-12 DOI:10.2196/65820
Gao Song, Cai-Qiong Zhang, Zhong-Ping Bai, Rong Li, Meng-Qun Cheng
{"title":"Assisted Reproductive Technology and Risk of Childhood Cancer Among the Offspring of Parents With Infertility: Systematic Review and Meta-Analysis.","authors":"Gao Song, Cai-Qiong Zhang, Zhong-Ping Bai, Rong Li, Meng-Qun Cheng","doi":"10.2196/65820","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The relationship between assisted reproductive technology (ART) and childhood cancer risk has been widely debated. Previous meta-analyses did not adequately account for the impact of infertility, and this study addresses this gap.</p><p><strong>Objective: </strong>Our primary objective was to assess the relative risk (RR) of childhood cancer in infertile populations using ART versus non-ART offspring, with a secondary focus on comparing frozen embryo transfer (FET) and fresh embryo transfer (fresh-ET).</p><p><strong>Methods: </strong>A literature review was conducted through PubMed, Embase, Cochrane, and Web of Science, with a cutoff date of July 10, 2024. The study was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY 202470119). Inclusion criteria were based on the PICOS (Population, Intervention, Comparison, Outcomes, and Study Design) framework: infertile or subfertile couples (population), ART interventions (in vitro fertilization [IVF], intracytoplasmic sperm injection [ICSI], FET, and fresh-ET), non-ART comparison, and childhood cancer risk outcomes. Data abstraction focused on the primary exposures (ART vs non-ART and FET vs fresh-ET) and outcomes (childhood cancer risk). The risk of bias was assessed using the Newcastle-Ottawa Quality Assessment Scale, and the evidence quality was evaluated with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Pooled estimates and 95% CIs were calculated using random effects models.</p><p><strong>Results: </strong>A total of 18 studies were included, published between 2000 and 2024, consisting of 14 (78%) cohort studies and 4 (22%) case-control studies, all of which were of moderate to high quality. The cohort studies had follow-up periods ranging from 3 to 18 years. Compared with non-ART conception, ART conception was not significantly associated with an increased risk of childhood overall cancer (RR 0.95, 95% CI 0.71-1.27; GRADE quality: low to moderate). Subgroup analyses of IVF (RR 0.86, 95% CI 0.59-1.25), ICSI (RR 0.76, 95% CI 0.26-2.2), FET (RR 0.98, 95% CI 0.54-1.76), and fresh-ET (RR 0.75, 95% CI 0.49-1.15) showed similar findings. No significant differences were found for specific childhood cancers, including leukemia (RR 0.99, 95% CI 0.79-1.24), lymphoma (RR 1.22, 95% CI 0.64-2.34), brain cancer (RR 1.22, 95% CI 0.73-2.05), embryonal tumors (RR 1, 95% CI 0.63-1.58), retinoblastoma (RR 1.3, 95% CI 0.73-2.31), and neuroblastoma (RR 1.02, 95% CI 0.48-2.16). Additionally, no significant difference was observed in a head-to-head comparison of FET versus fresh-ET (RR 0.99, 95% CI 0.86-1.14; GRADE quality: moderate).</p><p><strong>Conclusions: </strong>In conclusion, this study found no significant difference in the risk of childhood cancer between offspring conceived through ART and those conceived through non-ART treatments (such as fertility drugs or intrauterine insemination) in infertile populations. While infertility treatments may elevate baseline risks, our findings suggest that whether individuals with infertility conceive using ART or non-ART methods, their offspring do not face a significantly higher risk of childhood cancer. Further research, especially comparing infertile populations who conceive naturally, is needed to better understand potential long-term health outcomes.</p>","PeriodicalId":45538,"journal":{"name":"JMIR Cancer","volume":"11 ","pages":"e65820"},"PeriodicalIF":3.3000,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11921989/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JMIR Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.2196/65820","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: The relationship between assisted reproductive technology (ART) and childhood cancer risk has been widely debated. Previous meta-analyses did not adequately account for the impact of infertility, and this study addresses this gap.

Objective: Our primary objective was to assess the relative risk (RR) of childhood cancer in infertile populations using ART versus non-ART offspring, with a secondary focus on comparing frozen embryo transfer (FET) and fresh embryo transfer (fresh-ET).

Methods: A literature review was conducted through PubMed, Embase, Cochrane, and Web of Science, with a cutoff date of July 10, 2024. The study was registered with the International Platform of Registered Systematic Review and Meta-Analysis Protocols (INPLASY 202470119). Inclusion criteria were based on the PICOS (Population, Intervention, Comparison, Outcomes, and Study Design) framework: infertile or subfertile couples (population), ART interventions (in vitro fertilization [IVF], intracytoplasmic sperm injection [ICSI], FET, and fresh-ET), non-ART comparison, and childhood cancer risk outcomes. Data abstraction focused on the primary exposures (ART vs non-ART and FET vs fresh-ET) and outcomes (childhood cancer risk). The risk of bias was assessed using the Newcastle-Ottawa Quality Assessment Scale, and the evidence quality was evaluated with the Grading of Recommendations Assessment, Development, and Evaluation (GRADE). Pooled estimates and 95% CIs were calculated using random effects models.

Results: A total of 18 studies were included, published between 2000 and 2024, consisting of 14 (78%) cohort studies and 4 (22%) case-control studies, all of which were of moderate to high quality. The cohort studies had follow-up periods ranging from 3 to 18 years. Compared with non-ART conception, ART conception was not significantly associated with an increased risk of childhood overall cancer (RR 0.95, 95% CI 0.71-1.27; GRADE quality: low to moderate). Subgroup analyses of IVF (RR 0.86, 95% CI 0.59-1.25), ICSI (RR 0.76, 95% CI 0.26-2.2), FET (RR 0.98, 95% CI 0.54-1.76), and fresh-ET (RR 0.75, 95% CI 0.49-1.15) showed similar findings. No significant differences were found for specific childhood cancers, including leukemia (RR 0.99, 95% CI 0.79-1.24), lymphoma (RR 1.22, 95% CI 0.64-2.34), brain cancer (RR 1.22, 95% CI 0.73-2.05), embryonal tumors (RR 1, 95% CI 0.63-1.58), retinoblastoma (RR 1.3, 95% CI 0.73-2.31), and neuroblastoma (RR 1.02, 95% CI 0.48-2.16). Additionally, no significant difference was observed in a head-to-head comparison of FET versus fresh-ET (RR 0.99, 95% CI 0.86-1.14; GRADE quality: moderate).

Conclusions: In conclusion, this study found no significant difference in the risk of childhood cancer between offspring conceived through ART and those conceived through non-ART treatments (such as fertility drugs or intrauterine insemination) in infertile populations. While infertility treatments may elevate baseline risks, our findings suggest that whether individuals with infertility conceive using ART or non-ART methods, their offspring do not face a significantly higher risk of childhood cancer. Further research, especially comparing infertile populations who conceive naturally, is needed to better understand potential long-term health outcomes.

辅助生殖技术与不育父母后代儿童癌症风险:系统回顾和荟萃分析。
背景:辅助生殖技术(ART)与儿童癌症风险之间的关系一直备受争议。以前的荟萃分析没有充分考虑不孕症的影响,而本研究弥补了这一空白。目的:我们的主要目的是评估使用ART和非ART后代的不育人群儿童癌症的相对风险(RR),次要重点是比较冷冻胚胎移植(FET)和新鲜胚胎移植(fresh- et)。方法:通过PubMed、Embase、Cochrane和Web of Science进行文献综述,截止日期为2024年7月10日。该研究已在国际注册系统评价和荟萃分析协议平台(INPLASY 202470119)注册。纳入标准基于PICOS(人群、干预、比较、结果和研究设计)框架:不育或不孕夫妇(人群)、ART干预(体外受精[IVF]、胞浆内单精子注射[ICSI]、FET和新鲜et)、非ART比较和儿童癌症风险结局。数据抽象集中于主要暴露(ART与非ART以及FET与新鲜et)和结果(儿童癌症风险)。偏倚风险采用纽卡斯尔-渥太华质量评估量表进行评估,证据质量采用推荐评估、发展和评价分级(GRADE)进行评估。使用随机效应模型计算合并估计和95% ci。结果:共纳入2000年至2024年间发表的18项研究,包括14项(78%)队列研究和4项(22%)病例对照研究,均为中高质量研究。队列研究的随访期从3年到18年不等。与非ART妊娠相比,ART妊娠与儿童总体癌症风险增加无显著相关(RR 0.95, 95% CI 0.71-1.27;质量等级:低到中等)。IVF (RR 0.86, 95% CI 0.59-1.25)、ICSI (RR 0.76, 95% CI 0.26-2.2)、FET (RR 0.98, 95% CI 0.54-1.76)和fresh-ET (RR 0.75, 95% CI 0.49-1.15)的亚组分析显示类似的结果。特定的儿童癌症,包括白血病(RR 0.99, 95% CI 0.79-1.24)、淋巴瘤(RR 1.22, 95% CI 0.64-2.34)、脑癌(RR 1.22, 95% CI 0.73-2.05)、胚胎肿瘤(RR 1, 95% CI 0.63-1.58)、视网膜母细胞瘤(RR 1.3, 95% CI 0.73-2.31)和神经母细胞瘤(RR 1.02, 95% CI 0.48-2.16),未发现显著差异。此外,FET与新鲜et的头对头比较无显著差异(RR 0.99, 95% CI 0.86-1.14;质量等级:中等)。结论:总之,本研究发现,在不育人群中,通过抗逆转录病毒技术(ART)受孕的后代与通过非ART治疗(如生育药物或宫内人工授精)受孕的后代患儿童癌症的风险没有显著差异。虽然不孕不育治疗可能会提高基线风险,但我们的研究结果表明,无论不孕不育患者是使用抗逆转录病毒疗法还是非抗逆转录病毒疗法受孕,他们的后代都不会面临明显更高的儿童癌症风险。需要进一步的研究,特别是比较自然受孕的不孕人群,以更好地了解潜在的长期健康结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
JMIR Cancer
JMIR Cancer ONCOLOGY-
CiteScore
4.10
自引率
0.00%
发文量
64
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信